BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 7581098)

  • 21. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center.
    Powles R; Mehta J; Singhal S; Horton C; Tait D; Milan S; Pollard C; Lumley H; Matthey F; Shirley J
    Bone Marrow Transplant; 1995 Aug; 16(2):241-7. PubMed ID: 7581142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
    Reece DE; Barnett MJ; Connors JM; Klingemann HG; O'Reilly SE; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1993 Feb; 11(2):139-46. PubMed ID: 8435663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.
    Einsele H; Bamberg M; Budach W; Schmidberger H; Hess CF; Wörmann B; Meisner C; Straka C; Hebart H; Trümper L; Kröger N; Zander AR; Hegewisch-Becker S; Hossfeld DK; Schmidt H; Müller P; Schlimok G; Hertenstein B; Peest D; Metzner B; Frickhofen N; Kanz L; Bensinger WI
    Bone Marrow Transplant; 2003 Sep; 32(6):593-9. PubMed ID: 12953132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hematopoietic stem cell transplantation for treatment of acute leukemia].
    Harada M
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1387-95. PubMed ID: 10500524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Indications, technique and risks in bone marrow transplantation in adulthood].
    Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
    Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
    Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
    Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.